medical technology

Michael J. Hennessy Associates‚ Inc., Acquires Cure Media Group

Plainsboro-based Michael J. Hennessy Associates‚ Inc (MJH), a full-service healthcare education, market research, and communications company reaching more than 600,000 healthcare professionals, has acquired CURE Media Group ( from McKesson Specialty Health, a division of McKesson Corporation.

CURE Media Group, through its unique and award-winning products, has been a source of information and inspiration for patients and families on the cancer journey since 2002. CURE Media Group’s flagship product, CURE™ magazine, is the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer magazine in the United States focused entirely on cancer, with broad distribution to cancer patients, cancer centers, and advocacy groups. Through the magazine, live meetings, a resource guide for the newly diagnosed, the Extraordinary HealerSM national nursing award, and other books and online tools, CURE Media Group combines science and humanity to make cancer understandable.

CURE will join MJH’s acclaimed OncLive® platform of resources for the practicing oncologist. OncLive’s offerings include its website, with the most up-to-date information for professionals in cancer care; the renowned Peer Exchange and OncInsights™ video series; a full suite of monthly and quarterly publications; and the recently launched OncLive News Network,™ which provides the latest in breaking news on a 24/7 basis. OncLive is also the official communications partner of Physicians’ Education Resource® (PER®), the educational resource of choice for live and online activities focusing on oncology and hematology.

Through this acquisition, MJH continues to solidify its position as the fastest growing privately owned US healthcare media company, according to Kantar Media data. Mike Hennessy, chairman and CEO of MJH, said: “We are dedicated to preserving and improving the quality of healthcare throughout the world through research, education, and communication. We look forward to growing the CURE brand and further enhancing its exceptional reputation as a vital resource for patients and their caregivers. We will continue CURE’s rich history of featuring relevant content designed to help patients make informed decisions from diagnosis to treatment to survivorship.”

Tighe Blazier, president of MJH, added: “CURE makes an excellent addition to the MJH family. As cancer care continues to require increasingly informed conversations between patients and their healthcare teams, CURE will play an important role in all of our business units. It completes the loop between the physician and patient for OncLive and provides a forum for patient engagement within the PER-accredited medical education program, as well as a patient panel for HRA®—Healthcare Research & Analytics, our market research company.”

Related Articles: